CTNNB1 and hepatocellular carcinoma: A proportion of 27% of patients with HCC have gain-of-function mutations of CTNNB1 that code for ß-catenin, which may occur in addition to missense mutations of CTNNB1 that prevent phosphorylation of ß-catenin [72,73].